Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

122 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.
La Fleur L, Johansson AC, Roberg K. La Fleur L, et al. Among authors: johansson ac. PLoS One. 2012;7(9):e44071. doi: 10.1371/journal.pone.0044071. Epub 2012 Sep 25. PLoS One. 2012. PMID: 23049743 Free PMC article.
Role of lysosomal cathepsins in naphthazarin- and Fas-induced apoptosis in oral squamous cell carcinoma cells.
Johansson AC, Norberg-Spaak L, Roberg K. Johansson AC, et al. Acta Otolaryngol. 2006 Jan;126(1):70-81. doi: 10.1080/00016480510043422. Acta Otolaryngol. 2006. PMID: 16308258
Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines.
Farnebo L, Jedlinski A, Ansell A, Vainikka L, Thunell LK, Grénman R, Johansson AC, Roberg K. Farnebo L, et al. Among authors: johansson ac. Int J Mol Med. 2009 Oct;24(4):549-56. doi: 10.3892/ijmm_00000264. Int J Mol Med. 2009. PMID: 19724896
Combining factors on protein and gene level to predict radioresponse in head and neck cancer cell lines.
Farnebo L, Jerhammar F, Ceder R, Grafström RC, Vainikka L, Thunell L, Grénman R, Johansson AC, Roberg K. Farnebo L, et al. Among authors: johansson ac. J Oral Pathol Med. 2011 Nov;40(10):739-46. doi: 10.1111/j.1600-0714.2011.01036.x. Epub 2011 Apr 11. J Oral Pathol Med. 2011. PMID: 21481002
EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A, Ansell A, Johansson AC, Roberg K. Jedlinski A, et al. Among authors: johansson ac. J Oral Pathol Med. 2013 Jan;42(1):26-36. doi: 10.1111/j.1600-0714.2012.01177.x. Epub 2012 May 29. J Oral Pathol Med. 2013. PMID: 22643066
Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells.
Johansson AC, Ansell A, Jerhammar F, Lindh MB, Grénman R, Munck-Wikland E, Östman A, Roberg K. Johansson AC, et al. Mol Cancer Res. 2012 Sep;10(9):1158-68. doi: 10.1158/1541-7786.MCR-12-0030. Epub 2012 Jul 18. Mol Cancer Res. 2012. PMID: 22809838
YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer.
Jerhammar F, Johansson AC, Ceder R, Welander J, Jansson A, Grafström RC, Söderkvist P, Roberg K. Jerhammar F, et al. Among authors: johansson ac. Oral Oncol. 2014 Sep;50(9):832-9. doi: 10.1016/j.oraloncology.2014.06.003. Epub 2014 Jun 30. Oral Oncol. 2014. PMID: 24993889
Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A, Jedlinski A, Johansson AC, Roberg K. Ansell A, et al. Among authors: johansson ac. J Oral Pathol Med. 2016 Jan;45(1):9-16. doi: 10.1111/jop.12310. Epub 2015 Feb 10. J Oral Pathol Med. 2016. PMID: 25677871
The relationship between EMT, CD44high /EGFRlow phenotype, and treatment response in head and neck cancer cell lines.
Johansson AC, La Fleur L, Melissaridou S, Roberg K. Johansson AC, et al. J Oral Pathol Med. 2016 Oct;45(9):640-646. doi: 10.1111/jop.12423. Epub 2016 Jan 12. J Oral Pathol Med. 2016. PMID: 26757432
Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A, Garvin S, Johansson AC, Edqvist PH, Ponten F, Roberg K. Jedlinski A, et al. Among authors: johansson ac. J Oral Pathol Med. 2017 Oct;46(9):717-724. doi: 10.1111/jop.12545. Epub 2017 Jan 28. J Oral Pathol Med. 2017. PMID: 28036101
122 results
Jump to page
Feedback